Ownership history in SUPERSTRING CAPITAL MANAGEMENT LP · 8 quarters on record
This page tracks every 13F SEC filing in which SUPERSTRING CAPITAL MANAGEMENT LP reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 88,658 | -8,108 | -8.4% | 4.54% | $4.6M | $51.94 |
| 2025 Q2 | REDUCED | 96,766 | -87,156 | -47.4% | 4.95% | $4.2M | $43.18 |
| 2025 Q1 | REDUCED | 183,922 | -78,219 | -29.8% | 7.56% | $6.4M | $34.57 |
| 2024 Q4 | ADDED | 262,141 | +35,457 | +15.6% | 6.23% | $7.2M | $27.44 |
| 2024 Q3 | ADDED | 226,684 | +6,847 | +3.1% | 5.05% | $5.8M | $25.46 |
| 2024 Q2 | REDUCED | 219,837 | -133,670 | -37.8% | 7.02% | $5.6M | $25.33 |
| 2024 Q1 | ADDED | 353,507 | +147,181 | +71.3% | 7.23% | $10.9M | $30.92 |
| 2023 Q4 | INITIATED | 206,326 | — | — | 5.95% | $8.3M | — |
As of 2025 Q4 — sorted by position size